Annual report pursuant to Section 13 and 15(d)

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)

v3.23.1
Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)
 1 Months Ended 2 Months Ended 12 Months Ended
Aug. 03, 2022
USD ($)
$ / shares
shares
Aug. 01, 2022
USD ($)
$ / shares
shares
May 31, 2022
USD ($)
$ / shares
shares
Feb. 28, 2022
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Aug. 12, 2021
Jul. 31, 2021
Dec. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
State of incorporation         DE        
Date of incorporation         Aug. 03, 2018        
Common stock, conversion description         minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.        
Common stock, conversion ratio         1        
Working capital         $ 8,539,131        
Accumulated deficit         (44,207,272) $ (28,437,993)      
Cash         10,950,927 10,574,292      
Current liabilities         3,268,906 2,145,996      
Revenues         0        
Number of common stock sold | shares     11,111 263,729          
Sale of common stock, price per share | $ / shares     $ 9 $ 9          
Gross proceeds from sale of common stock $ 9,100,000   $ 99,999 $ 2,373,561 2,473,560 5,742,171      
Current cash reserves         10,950,927 10,574,292     $ 663,457
Gross proceeds from initial public offering         11,500,000        
Cash equivalents         $ 0 $ 0      
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]         true        
Change in Accounting Principle, Accounting Standards Update, Adoption Date         Jan. 01, 2022        
Accounting Standards Update [Extensible Enumeration]         us-gaap:AccountingStandardsUpdate201602Member        
IPO                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of common stock sold | shares   2,000,000              
Sale of common stock, price per share | $ / shares   $ 5              
Issuance of common shares   $ 1,099,360     $ 8,750,095        
Gross proceeds from initial public offering   $ 10,000,000              
Overallotment Option                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of common stock sold | shares 300,000                
Sale of common stock, price per share | $ / shares $ 5                
Gross proceeds from initial public offering $ 1,500,000                
Offering and Overallotment                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Cash issuance cost, net 2,406,170                
Issuance of common shares $ 9,093,830                
MAIA Drug Development Corporation                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
State of incorporation         TX        
Date of incorporation         Sep. 10, 2018        
MAIA Biotechnology, Inc. | THIO Therapeutics, Inc.                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Ownership percentage by parent             93.30%    
Minority stockholder ownership percentage             6.70%    
MAIA Biotechnology, Inc. | MAIA Drug Development Corporation                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Ownership percentage by parent               100.00%  
DGD Pharmaceuticals Corporation                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
State of incorporation         DE        
Date of incorporation         Apr. 01, 2019